WELL Health Technologies Corp. (WELL) Earnings Call Transcript
August 6, 2026
Earnings Call Speaker Segments
Good afternoon, everyone, and thank you for joining the WELL Health Technologies Corp second quarter 2026 conference call. Right now, every line has been placed in listen-only mode. After the presentation, there will be a question-and-answer session. Should you require assistance at any point during this call, just press star zero to reach the operator. Today is Thursday, August 6, 2026, and this call is being recorded. I'll now hand the conference over to Pardeep Sangha. Please go ahead.
Thank you, operator, and welcome everyone to the conference call on WELL Health's fiscal second quarter financial results for the period that ended June 30th, 2026. With me today are Hamed Shahbazi, our Chairman and CEO, and Eva Fong, the company's CFO. I believe everyone has received the copy of our financial results press release that went out earlier today. Parts of today's call, apart from historical performance, contain statements of forward-looking information as defined under applicable securities laws, including future-oriented financial information and financial outlook information. Such forward-looking statements carry known and unknown risks, uncertainties, assumptions, and other factors, many of which lie outside of WELL's control, and these may cause actual results, performance, or achievements of WELL to differ materially from the anticipated results, performance, or achievements implied by those forward-looking statements. These factors are described further in today's press release and in our management discussion and analysis. We provide forward-looking statements only for the purpose of giving information about management's current expectations of plans relating to the future. We do not undertake or accept any obligation or undertaking to publicly release any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, assumptions, or circumstances on which any such statement is based, except where required by law.
On this conference call, we might refer to certain measures — adjusted gross profit, adjusted gross margin, adjusted EBITDA, adjusted EBITDA margin, shareholder EBITDA, adjusted net income, and adjusted free cash flow — and all of these are non-GAAP and non-IFRS figures. For further detail on the way we define these terms, please see the definitions provided in today's press release as well as in our management's discussion and analysis. The company views adjusted EBITDA as a meaningful financial metric, since it captures cash generated from operations that the company can deploy toward funding working capital requirements, servicing future interest and principal debt repayments, and funding future growth initiatives. Adjusted EBITDA should not be construed as an alternative to net income or loss determined in accordance with IFRS. With that, let me hand the call over to Mr. Hamed Shahbazi, Chairman and CEO.
Thanks, Pardeep, and hello everyone. We're glad you could all be with us. Before we turn to the quarter, I'd like to pull back a bit and point to what WELL has achieved across the last several months. No single financial result was what defined this quarter. What defined it was execution on each of the key pillars of our strategy: growing our Canadian clinics platform through acquisitions and organic growth, hitting a major profitability milestone earlier than planned, reinforcing our balance sheet, and freeing up additional growth capital for WELLSTAR so it can speed up its next phase of growth. The specific highlights are these. First, for WELL Canada we hit our CAD 100 million adjusted EBITDA run rate milestone three quarters early, and at margins well ahead of what we originally expected. Second, we closed our inaugural CAD 150 million senior unsecured bond offering, reinforcing our balance sheet by pushing out our debt maturity profile to 2031. Third, last week WELLSTAR closed a CAD 50 million financing made up of both primary and secondary components alongside its planned standalone public listing in September, drawing high-quality institutional investors and putting the business in position for its next phase of growth. Fourth, we closed two highly strategic acquisitions, Ontario Imaging Diagnostics and UnionMD, which deepen our leadership in Canadian outpatient healthcare while adding roughly CAD 22 million in annual EBITDA.
All of that, when you put it together, shows our strategy is delivering. What we're constructing is a healthcare platform that is bigger, of higher quality and better capitalized — one that produces stronger profitability right now and at the same time opens up several paths for growth down the road. That execution is the reason we're raising our 2026 guidance as of today. Under the new 2026 guidance, revenue is CAD 1.58 billion-CAD 1.65 billion, versus the prior guidance of CAD 1.55 billion-CAD 1.65 billion. The low end has been lifted and the range has been narrowed toward the upper side. On adjusted EBITDA, the new guidance stands at CAD 185 million-CAD 195 million, which is a full CAD 10 million above CAD 175 million-CAD 185 million. As you can see, the improvement in the EBITDA guidance range is considerably larger than the one in the revenue guidance range, and that reflects our execution and our focus on growth opportunities with higher margins. Turning now to the quarter. Q2 revenue came in at roughly CAD 400 million, a rise of 12% year-over-year. Adjusted EBITDA was CAD 48.1 million, a decline of 3%, while adjusted EBITDA attributable to WELL shareholders was CAD 35 million, lower by about 6%. Normalized — that is, after accounting for the Circle Medical deferred revenues — revenue was up 14% to CAD 395.6 million, adjusted EBITDA was up 8% to CAD 43.3 million, and adjusted shareholder EBITDA was up 4% to CAD 32 million.
Regarding the difference between what we reported and normalized figures, during this quarter we again saw CAD 9.7 million of deferred revenue in Q2 2025, compared with CAD 4.8 million in the current quarter. That swing, together with approximately CAD 8.7 million of one-time retro reimbursement revenue from the Canadian patient services business in the prior-year period, held back our reported growth rate, despite the fact that the underlying business expanded at a much quicker pace. Keeping that in mind, let's move on to the remaining financial highlights. Adjusted gross profit came in at CAD 178.4 million, a rise of 12% year-over-year, while adjusted gross margin gained ten basis points to reach 44.6%. After normalizing for deferred revenues, adjusted gross profit stood at CAD 173.6 million, an increase of 17%, and margin grew 90 basis points to 43.9%. The expansion in our margin is still being powered by the change in revenue mix toward higher-margin WELLSTAR, diagnostics, and executive and longevity health revenue. Adjusted net income was CAD 11.6 million in Q2 2026. On a normalized basis, adjusted net income came to CAD 9.2 million. Later in the call, I'll have Eva take you through the detailed bridge underlying these net figures. Before that, I'd like to focus briefly on June, since how the quarter was shaped matters just as much as the total.
We came out of Q2 in a much stronger position than when we went in. For June, revenue rose 24% year-over-year, or 28% on a normalized basis for deferred revenues. June adjusted EBITDA increased 12% as reported and 43% normalized. Adjusted shareholder EBITDA for June was higher by 28% reported and 66% normalized. June stood out as a solid month inside the quarter, and that momentum carried into our margins too. Those positive June results also came from the recent OID and UnionMD acquisitions, along with gains in the Wisp business, again in June. That exit rate is what supports the raised guidance we are giving today, and it is the strongest signal we have about where the Canadian business is headed in the second half. What these results show is a business that keeps compounding. Now to our operational metrics. WELL's clinic network currently takes in more than 5,000 providers, among them over 1,500 physicians in Canada. Outside our own clinics, WELLSTAR's technology serves more than 45,000 unique providers. Keep in mind, the whole country has only just over 100,000 physicians. Across the system, including Canada and the U.S. and excluding HEALWELL AI, patient visits rose 19% year-over-year to 2 million, with 5% organic growth. Patient visits in Canada hit 1.4 million, an increase of 28% year-over-year, or 5.6 million visits on an annualized run rate basis.
Overall care interactions—what we call patient visits combined with technology interactions—came in above 3.1 million for the quarter, rising 21%, including 11% organic growth. The organic growth rate for care interactions is outpacing that of patient visits, which shows you that our technology layer is taking on more and more of the work alongside our clinical platform. Moving on. These strong financial and operational results stem from something that matters more: the tangible, real-world difference our platform makes for patients and providers each and every day. Let me share three fresh and updated illustrations of the impact we are having on Canadian healthcare. The first: WELL cardiologists are seeing patients in roughly two weeks, compared with the 15.3 week industry average reported by the Fraser Institute. Second, technology enablement at WELL Clinics has produced an 80% reduction in no-shows, meaning provider time gets used more efficiently and effective wait lists get shorter for everyone else. Working together with HEALWELL, we have now gathered more than 85,000 WELL Trust consents as of June 30th, which gives patients a consent-first route to take part in research and data-driven care. These efficiencies are not theoretical. They are measured, repeatable improvements at scale. They are the reason patients and providers keep choosing WELL.
Now turning to our team. It's a real pleasure to share that four outstanding leaders came on board at WELL during this quarter, helping drive the coming stage of our expansion. Derek Clark is now our COO, Chief Operating Officer, and he brings more than 20 years of healthcare and digital health leadership experience from TELUS Health and GE HealthCare to bolster the upcoming phase of operational delivery and scaling. We're glad to have you, Derek. Loreto Grimaldi came aboard as Chief Legal Officer, with over 25 years of leadership in legal, governance, and M&A, having previously been at MedAvail Technologies Inc. and, most recently, serving as CEO of Tricor Automotive Group. Welcome aboard, Loreto. Kaytek Przybylski has joined us as Chief Digital and Information Officer, and he brings over 25 years of experience in enterprise technology and digital transformation, most recently serving as Chief Digital Officer at Lantern and, before that, as EVP and Chief Data and Technology Officer at LifeWorks, formerly known as Morneau Shepell. Welcome, Kaytek. Dr. Andrew Bond has come on as Chief Health Officer and Head of Public Sector. Andrew brings over two decades of clinical and health system leadership, most recently as SVP and Chief Medical Officer at GreenShield. Andrew now oversees clinical governance throughout the WELL group and is leading our public sector strategy, which includes the One WELL vision, and that's what I'd like to walk you through next.
Thanks, Andrew. The upcoming slides set out the strategic framework, and I'll keep this short since nothing about it has shifted. Healthcare in Canada is extraordinarily complicated and confronts six structural pressures: access, provider burnout, chronic disease, acute capacity, the fiscal ceiling, an aging population, and data fragmentation. I won't go into the specifics of all of that right now, but this slide puts a size on each one of these challenges. Practically everything you come across in the news falls into one of those six. That's the big-picture picture of where Canadian healthcare sits today. I want to demonstrate how WELL is purpose-built to tackle these pressures simultaneously. WELL's vision is to serve as the operating system underpinning outpatient healthcare at scale for a more modern Canadian healthcare system. We are the sole integrated example in the country that brings together care delivery at scale, the technology to run and continuously improve that delivery, and an intelligence layer that converts the resulting data back into better care and better tools for providers. Clinics that deliver care, technology that runs it, and AI that makes it smarter. Our above-average NPS or Net Promoter Score show that patients value our tech-enabled approach that respects their time, and we keep working hard to improve our offerings every day.
Moving to One WELL now. Across the WELL group of companies, we refer to our integrated offering as One WELL. Within Canada, that includes more than 275 clinics and over 1,500 physicians, together delivering 5.6 million annualized visits, and it also takes in the country's largest diagnostic group, with more than 85 locations. For those providers, WELLSTAR's technology handles intake, scheduling, clinical decision support with a human always kept in the loop, billing, and cybersecurity. Alongside that, HEALWELL's clinical AI identifies patients with rare and chronic disease for our clinicians and for our enterprise life sciences partners. We have built ourselves as an interoperable system builder rather than a silo builder, and that fits with the Bill S-5 Connected Care for Canadians Act, which is now before the House of Commons of Canada, as well as with the Pan-Canadian Interoperability Roadmap, to which WELLSTAR and HEALWELL are leading contributors. One WELL is all about bringing together the best of the WELL group to support Canadians' healthcare at a moment when Canadians supporting Canadians matters more than ever. Moving to our capital structure: on June 15, 2026, we closed WELL's inaugural senior unsecured notes offering — CAD 150 million aggregate principal amount of 6.875% senior unsecured notes due 20 to 31, issued at par and ranking equally with our other senior unsecured indebtedness.
The money raised from this offering is going toward paying off our convertible debentures maturing in December 2026, with whatever remains going to general corporate purposes. This offering drew more demand than it had available and was led by BMO Capital Markets on behalf of the bank syndicate. The interest we witnessed throughout that syndicate represents a significant show of confidence from fixed income investors regarding how durable our cash flows are, and as it happens, it extends our maturity profile out to 2031. Now let's turn to WELL Canada, which covers Canadian clinics, WELLSTAR, and CYBERWELL, while HEALWELL is not included. WELL Canada brought in revenue of CAD 176.6 million, a rise of 32% year-over-year, or roughly 41% once you exclude the one-time reimbursement lift from the base in the prior year. As I noted earlier, that one-time retro reimbursement revenue came to about CAD 8.7 million. Adjusted EBITDA reached CAD 27.4 million, climbing 19% on a reported basis, or approximately 56% when that same prior year item is excluded. Whichever way you frame it, this reflects the compounding growth in our Canadian business that supports the guidance increase we're giving today. Canadian clinics, which span both primary care and diagnostics, produced revenue of CAD 151.6 million and adjusted EBITDA of CAD 22.3 million, compared with CAD 114.9 million and CAD 18.2 million a year ago.
Our primary care adjusted EBITDA margin widened to 8.6%, up from 5.2%, which reflects acquisitions that were accretive as well as ongoing progress under our clinic transformation program. Looking at it on a trailing basis, revenue from Canadian clinics has compounded at a 47% CAGR, while adjusted EBITDA has compounded at a 44% CAGR. At the beginning of 2022 the network stood at 128 clinics, and today it numbers more than 275. Across our network of Canadian clinics, patient visits came to 1.36 million, a rise of 28%. Billable providers totaled 2,444, an increase of 26%. Keep in mind that these numbers take in our UnionMD and OID acquisitions, which add their entire provider count but contribute just one month of visits, since they closed in June. If you set those acquisitions aside, visits kept growing at a faster pace than the provider count. Visits per billable provider climbed to roughly 576, compared with roughly 584, and with roughly 449 two years earlier. AI transcription and digital workflows continue to be a major force behind that productivity improvement. When those acquisitions are included, visits per billable provider came to roughly 557. Stepping back, in a healthcare setting that is heavily burdened, productivity gains like these truly matter. Now shifting to M&A activity among Canadian clinics. In Q2 2026 we had a substantial quarter, closing three transactions that brought in 23 clinics, CAD 67.8 million of annual revenue, and 117 additional providers.
Q2's results are primarily a reflection of the OID and UnionMD deals we discussed earlier. Now, on the pipeline side, the overall WELL Canada pipeline is still robust — when you factor in pre-LOI targets, that's upwards of 30 targets engaged, representing over CAD 340 million in annual revenue and more than 70 clinics. As we've said previously, when we refer to WELL Canada, that covers Canadian clinics, WELLSTAR and CYBERWELL, while all of HEALWELL sits outside that definition given its international emphasis. Within WELL Canada, revenue tied to LOIs or at an advanced stage comes to roughly CAD 193 million, spread across five signed LOIs plus unsigned LOI opportunities. Add in the balance sheet flexibility our new bond offering provides, and we have solid visibility into our Canadian growth trajectory through 2026 and beyond. Moving over to WELLSTAR: last week we announced that WELLSTAR completed a brokered private placement, generating gross proceeds of CAD 50 million alongside its planned standalone listing on the TSX Venture Exchange. That financing consisted of CAD 36.2 million in new treasury subscription receipts and CAD 13.8 million stemming from a secondary offering by an existing shareholder that was not WELL. It was anchored by a large Canadian bank-owned asset manager, along with new institutional investors and existing shareholders, and led by TD Securities, RBC Capital Markets and Stifel on behalf of a syndicate of agents.
WELLSTAR should start trading on the TSX Venture Exchange in September 2026. As you might remember, two years back we stated our aim for WELLSTAR to reach roughly CAD 100 million in revenue by the time it became publicly listed, and that target has now been met. For 2026, WELLSTAR is projected to bring in about CAD 95 million in revenue, with an anticipated adjusted EBITDA margin of around 21%, and a three-year organic revenue growth goal exceeding 20%. Listing as a standalone entity provides WELLSTAR with stronger strategic flexibility, better access to growth capital, and more visibility among investors. The proceeds will be used for strategic acquisitions, AI-driven product innovation, organic growth initiatives, and general corporate purposes. Executives from WELL and WELLSTAR, along with WELL Health itself, took part in the offering, and WELL Health is expected to stay a majority long-term controlling shareholder and a growing customer. Turning now to WELLSTAR's results. WELLSTAR brought in revenue of CAD 23 million, a 37% increase from CAD 16.8 million a year earlier. Adjusted EBITDA came to CAD 5.8 million, up 32% from CAD 4.4 million. Following roughly CAD 193,000 in one-time public company costs related to preparing for the listing, adjusted EBITDA stood at CAD 5.6 million, still up 27%, keeping its rule of 40 performance intact.
Moving on, I want to talk about the strategic alternatives reviews we have underway for our U.S. care delivery assets — CRH Medical, Wisp, and Circle Medical. More than 10 parties are currently involved across those three processes, at differing stages of review, and they break down roughly evenly between strategic acquirers and financial sponsors. Although we do have active, engaged parties in each process, none has progressed to a point where disclosure would be appropriate; in line with our obligations, we'll update the market promptly once that changes. One structural detail deserves mention: WELL holds 100% of CRH Medical's shares, while in Wisp and Circle Medical we are the controlling shareholder, with ownership of just over 50% — 53% in Circle Medical and as well in Wisp. That, together with its scale, explains why CRH carries the greatest weight in our financial profile. Briefly on business performance: Wisp got off to a difficult start this year, posting losses through the first five months, but came back to profitability in June with a sharper focus on margins and cost management. Quarterly revenue came in at $29.3 million, up from $28 million, and adjusted EBITDA was a loss of $200,000, compared with an EBITDA profit of $866,000 for Q2 2026.
Just for June, adjusted EBITDA came in above CAD 1.2 million. Circle Medical posted revenue of $29.5 million versus $34 million year over year — that gap comes from IFRS 15 deferral timing, not from any shift in the business itself. Normalized Circle saw modest growth, and the team remains focused on improving margins in compliance while adding four states by year-end. CRH Anesthesia, along with provider staffing, brought in combined revenue of $129.6 million, a rise of 5%, and combined adjusted EBITDA of $24.9 million, up 4%. The year-over-year comparison took a hit from the Radar staffing business, which saw some attrition among its customers. The rest of the staffing business kept performing well, and so did the anesthesia business focused on GI services. On the whole, the team has done a great job keeping the business healthy and growing. With that, I'll hand the call over to Eva, who will take you through the remainder of our financial results.
Thank you, Hamed. Good afternoon, everyone, and thanks for being with us today. To start, I'll take you through the bridge from Q2 2025 revenue of CAD 356.7 million to Q2 2026 revenue of CAD 404 million. On the chart's left side, if we remove CAD 9.7 million of Circle Medical net deferral impact from Q2 2025, that brings us to normalized Q2 2025 revenue of CAD 347 million. Then, taking out CAD 8.7 million of one-time reimbursement lift in Canadian Patient Services revenue booked in Q2 2025 for services delivered in earlier quarters, we see the net growth of our business: CAD 51.2 million from WELL Canada plus CAD 6.1 million from U.S. Patient Services and other businesses including HEALWELL and WELL Research. That lands us at normalized Q2 2026 revenue of CAD 395.6 million. On the chart's right side, adding CAD 4.8 million of Circle Medical net deferral impact in Q2 2026 brings us to Q2 2026 revenue of CAD 404 million. WELL Canada's CAD 51.2 million of growth came from organic and inorganic growth across our Canadian clinics and WELLSTAR businesses. The Adjusted EBITDA bridge follows a similar pattern. As this slide shows, it bridges from Q2 2025 Adjusted EBITDA of CAD 49.7 million to Q2 2026 Adjusted EBITDA of CAD 48.1 million.
Starting on the chart's left-hand side, if we take out CAD 9.7 million in net deferral impacts from Circle Medical, that brings us to normalized Q2 2025 Adjusted EBITDA of CAD 41.1 million. Then, by stripping away CAD 5.4 million of one-time reimbursement lift in Canadian Patient Services revenues, we get a clearer view of how Adjusted EBITDA actually grew. Adjusted EBITDA for WELL Canada rose by roughly CAD 9.8 million, and U.S. Patient Services Adjusted EBITDA was up CAD 2.8 million versus Q2 of last year, which brings us to normalized Q2 2026 Adjusted EBITDA of CAD 43.3 million. Moving to the chart's right-hand side, adding CAD 4.8 million of Circle Medical net deferral impact in Q2 2026 takes us to Adjusted EBITDA of CAD 48.1 million for Q2 2026. The underlying net Adjusted EBITDA growth at WELL Canada mirrors the ongoing revenue and margin expansion across our Canadian clinics and WELLSTAR businesses. Now for Adjusted net income. This slide lays out the bridge from our Q2 2025 Adjusted net income of CAD 25.8 million to Q2 2026 Adjusted net income of CAD 11.6 million. Likewise, on the chart's left side, taking out the CAD 4.9 million Circle Medical net deferral impact brings us to normalized Q2 2025 Adjusted net income of CAD 20.9 million.
Starting from there, we take out CAD 3.8 million of one-time reimbursement lift from Canadian Patient Services revenues. We had CAD 8.2 million in legal fees and other costs, plus CAD 3.9 million of higher interest expense, and those were partly offset by CAD 3.5 million of favorable non-operating items and CAD 0.6 million of net growth, which brings us to normalized Q2 2026 adjusted net income of CAD 9.2 million. On the right side of the chart, if you exclude CAD 2.4 million of Circle Medical net deferral impact in Q2 2026, that gets us to adjusted net income of CAD 11.6 million in Q2 2026. Just for clarity, non-operating items take in depreciation expense, foreign exchange gain and loss, gain on disposal of assets, and non-controlling interest, or NCI, included in net income. The rise in non-operating items is partly because of an increase in NCI from recent acquisitions. Legal and other costs take in litigation settlement and defense costs, net of insurance recovery. Moving on to free cash flow. Adjusted free cash flow attributable to shareholders came in at CAD 11.7 million in Q2 2026, in line with Q2 2025. The bridge shows that CAD 2.5 million of higher spend on corporate and WELL Research, CAD 1 million of higher cash interest, and CAD 3.6 million of higher capital expenditures were partly offset by CAD 3.3 million of lower cash taxes and CAD 3.8 million of net growth.
Higher capital spending is tied to upgrades at clinics and renovations of important clinic and private care sites. Those elevated costs should ease somewhat, although maintenance CapEx will be a bit higher. With our diagnostic business now larger, free cash flow conversion should strengthen as the investment period settles down over the back half of the year. Now to the balance sheet at June 30th, 2026. As of June 30th, 2026, WELL had cash and cash equivalents of CAD 130.6 million, versus CAD 133.8 million on December 31st, 2025. Loans and borrowings totaled CAD 628.7 million as of June 30th, 2026, against CAD 425.4 million at December 31st, 2025, which mirrors credit facility drawdowns used to fund acquisitions in the period before the bond offering Hamed referenced earlier. We continue to comply fully with every financial covenant under our syndicated credit facilities with JPMorgan in the U.S., RBC and The Bank of Nova Scotia in Canada. Over the six months ended June 30th, 2026, cash generated from operating activities was CAD 54.4 million, CAD 176.6 million went to investing activities—mainly CAD 152 million for business and asset acquisitions—and financing activities produced CAD 118.3 million, chiefly net credit facility proceeds ahead of the bond offering.
Back in May 2026, we renewed our normal course issuer bid program, and during Q2 2026 we bought back 162,600 shares in total. As permitted, we anticipate carrying on with the NCIB program for the rest of 2026. The bond proceeds are designated for repaying the convertible debentures that come due in December 2026, and with the ongoing room available under our credit facilities, we're in a very strong position to keep financing expansion in Canadian clinics and WELLSTAR. That wraps up my financial update. I'll hand the call back to Hamed now.
Thanks, Eva. Moving now to what lies ahead. The guidance figures were already presented at the start of the deck, so there's no need for me to go over them again. As we've talked about, particularly regarding EBITDA, those figures reflect a solid upward shift in expectations. What I'd like to add at this point are a couple of fresh benchmarks for how we view future growth, given that the CAD 100 million WELL Canada milestone has now been achieved. To start with, WELL Canada aims to hit a revenue run rate above CAD 1 billion by the close of 2028, counting both organic growth and acquisitions. Next, WELL Clinics alone is shooting for a run rate exceeding CAD 100 million in adjusted EBITDA by the finish of this year, 2026. In addition, WELLSTAR, as I noted before, should start trading on the TSX Venture Exchange come September. Our approach to capital allocation hasn't changed. Canadian clinics stay the top priority for additional WELL parent company capital, and that is likewise the main reason behind the WELLSTAR listing that is now in progress. To wrap up our presentation today: Q2 produced a Canadian business that hit its CAD 100 million EBITDA milestone three quarters ahead of schedule, a first-time bond offering that strengthens our balance sheet, and a fully funded WELLSTAR listing just weeks off.
That's the reason we lifted our guidance today. I want to express real gratitude to our board of directors, to our leadership teams and support staff around the globe and throughout every one of our operating subsidiaries, and most of all to our healthcare practitioners and frontline workers, who make a difference in patients' lives each day. Thank you as well to you — our retail and institutional shareholders and analysts — for your continued support. Operator, we'll now open the call for questions.
Thank you. Ladies and gentlemen, we're going to start the question-and-answer portion at this point. If you'd like to ask something, kindly press the star key and then the one key on your touch-tone telephone. A prompt will sound to confirm that your hand has been raised. In case you'd prefer to withdraw from the polling process, kindly press star and then two, and should you be on a speakerphone, please pick up the handset prior to pressing any keys. David Kwan with TD Cowen, please go ahead.
Thanks. Good afternoon. Hamed, I was hoping you could speak about WELLSTAR, and especially the solid increase in e-referral volumes that we saw during the first half of this year. What's driving that volume growth, and how do you expect it to develop over the next year or two?
Thanks, David. Broadly, we achieved a fairly notable victory in Ontario during the past year. As you might recall or know, there was a very substantial procurement process that, even though we had done some piloting beforehand, essentially narrowed things down to three vendors who were then presented to every region throughout the province—and every one of those regions ultimately chose OceanMD. That was a hugely important moment for OceanMD and, I believe, really showed the strength of the product and the level of engagement behind it. We keep seeing e-referral expansion pretty much across the board, but clearly that major Ontario win represented a substantial step-function improvement for us. Look, we keep seeing plenty of chances for OceanMD to come out ahead. If you consider where OceanMD has been successful so far, we hold key contracts stretching from British Columbia all the way to Ontario, through to Nova Scotia and elsewhere. We're also witnessing considerable growth and interest from additional provinces. I think that's a terrific story, and it's one we'll be following closely on behalf of investors.
Thanks. I was just curious if there was any update on BC. Obviously, you made an announcement — I believe that was a couple of years back, a year and a half, maybe two years ago — about how the ramp is progressing in BC.
Our BC operation keeps expanding. I should note that it remains clearly below markets such as Ontario, where large-scale pilots have taken place and where efforts have been underway for a considerably longer period. Such initiatives inevitably require some time, since you truly have to bring both the referring doctors and the doctors receiving those referrals onto the program, and that involves a certain amount of lead time. Every day brings further strides, and we feel enthusiastic about what lies ahead for BC too.
Thank you. Perhaps just one final question. Compared with, say, a couple of years back, when you were considerably more active on that front, there has been relatively little discussion about clinic absorptions. Are you seeing fewer opportunities for clinic absorption in today's market? Could you perhaps discuss what share of the pipeline they would represent?
Right, and that's a good point, David. No, we're certainly doing fewer of them, and a big part of that comes down to how much bandwidth our clinic transformation team has. As you can see, there's a lot of activity around the clinic acquisitions we're pursuing. We simply need to be thoughtful and selective regarding where those resources go. At this point we'll likely focus more on areas such as absorptions, mainly because we've deployed a fair amount of capital this year, particularly with OID and UnionMD marking the cap on our capital allocation activity. You'll likely see a few more, but bear in mind that absorptions require considerably more time and energy compared with a standard clinic. We're seeing really meaningful EBITDA gains now. Like our capital, our clinic transformation time is finite, and as prudent allocators of that time and expertise we have to take that into account. We're just approaching it far more strategically.
Much appreciated, and thank you.
Paradigm Capital's Daniel Rosenberg, you have the floor.
Hi there, and thanks for taking my question. My first one is about the M&A process. I appreciate that you broke out some of the LOIs in the pipeline versus the total pipeline. I was wondering whether you could speak to how you're thinking about M&A across the different divisions that you have—whether that's allocating capital, allocating resources, or otherwise, how are you dividing up the resources you have?
Yeah, no, that's a really good question. Look, you'll see that especially in this month, and honestly across the whole year, we've been putting capital into areas with higher margins. That's very much by design. Broadly speaking, I'd say most of our EBITDA in Canadian clinics does come from diagnostic imaging within our MyHealth platform — the legacy one that we really built on top of. We're big fans of that business. We believe it's one that does particularly well in a world that's increasingly disrupted by AI. It's one of the few areas where AI genuinely helps augment what you can do and helps you deliver care faster. It isn't an area where we see any sort of friction or any sort of autonomous service delivery. I'm talking many years downstream here. Margins are strong, and thanks to AI enhancements, we expect throughput to be higher. We remain very fond of that business. As for our UnionMD acquisition, if you look at it, that one has a great deal to do with procedural health — different processes and procedures, pain injections, light surgical-like aesthetic treatments, dermatological sorts of procedures. These are the kinds of things, non-aesthetic Botox uses, that address various different health ailments.
You know, these are the kinds of higher-margin segments we're really fond of. Take our e-referral business, for instance — in Alberta, as you might recall, we acquired that e-referral asset during the prior quarter. Right now it's doing extremely well. I'd say the advantage of having gotten this far along in our M&A program is that we now understand all those various niche areas far better, and we've got a strong handle on what their margins look like and how they grow. Since we're centralizing and thinking through how we allocate capital, we're quite selective about where that capital goes. The longevity and executive health segments, for example, have also delivered really nicely for us. Plenty of the public clinics keep improving for us too. That said, I'd tell you we're far more discerning about which public clinics we bring on, since their margins present more of a challenge compared with certain private options. I hope that gives you some sense of it — yes, we lean toward the higher-margin segments, where the juice is worth the squeeze, including from a clinic transformation standpoint as well.
Thank you. I appreciate it. This is somewhat related, and it's my last question. Regarding capital allocation, you made a couple of larger acquisitions this quarter. I'm curious how you're viewing debt levels and that balance. Clearly, there's a growth opportunity through M&A, but near term, there are also debt levels, repayments, and the recent debt instrument you secured. Any commentary on where you're comfortable with the balance sheet relative to the growth opportunities you have, and I'll pass the line. Thank you.
Yes, that's a really good point. So here's how I see it: as we get better at generating EBITDA and grow organically, we're going to see more EBITDA come back in. That naturally exerts pressure to bring our leverage ratio down, and we'll redeploy that capital. This ties into what I said about doing lower-end clinics. Some of those lower-end clinics may now be part of what we pursue, since they're much more capital efficient for us. They take a bit more time, but I'd say that for now, we've worked through some of those bigger purchase ticket items. As the divestiture processes mature, there will be extra capital that we'll deploy there — I mean for bigger ticket items — but even so, I think you'll keep seeing a healthy diet of bolt-ons happening. I'd say we probably return to a more normalized M&A rhythm. We'll keep the bigger ticket items warm as we bring forward non-dilutive capital to help us take on those bigger items.
That's great, thank you.
Justin Keywood from Stifel, you have the floor.
Hello there, and thanks for taking my call. It's good to see these results. Regarding the new WELL Canada target of CAD 1 billion by 2028, that's a pretty big step up from where we are now, at a CAD 700 million run rate. My assumption is that there's some potential for operating leverage if that goal is achieved. What kind of margin profile should we be expecting?
Appreciate that question. So, broadly speaking, we believe margins are trending upward. Right. And to build on the earlier question-and-answer exchange we just went through, where I touched briefly on the absorptions — clearly, at the outset, absorptions do tend to pull overall margins down. Overall, though, considering how much more high-margin revenue we are bringing in and will bring in, I really do think that, on balance, margins will go up. That's roughly our objective. We'll be quite deliberate about it. While that's a goal, what matters just as much to us is avoiding any erosion of margin. That, I think, is what makes it such a compelling goal. Now, let me be clear: achieving that does mean we need to obtain some liquidity from our U.S. assets so we can deliver on some of that. We're confident that will come about in due time.
Got it. Regarding that organic momentum you mentioned with the Canadian clinic network, it appears quite strong, sitting in the low double-digit range. I'm curious whether anything specific during the quarter helped push that organic growth rate. We're aware the generic GLP-1 has only just reached Canada. Is that making a difference, or are there any other notable health trends worth mentioning?
Look, over time our organic growth has generally been really robust. It fluctuates a bit. Naturally, I'd note that holding it at a higher level becomes tougher as the figures grow larger. Broadly, in healthcare, organic growth tends to land somewhere between roughly flat and about 3%. For a very substantial stretch, we've been performing considerably above that. What's fueling much of it for us at present, I'd say, is genuinely the best practices in tech enablement strategies that we're putting to work. A great deal of that relates to WELLSTAR's clinic orchestration and physician empowerment tools. And I'll add that we're now beginning to see wider deployment of some of the HEALWELL stuff too. On the whole, I believe tech enablement will be the leader, along with the mix of what we bring into the network and how we power those clinicians. Once more, we're staying very deliberate as we grow. The eConsult business is a prime example. We brought that on only a couple of quarters ago, and already we're seeing meaningful double-digit gains in performance from that asset, which, as you might recall, was a fairly material asset.
Our goal is twofold: to stimulate and unlock expansion within the business we already have, while also making sure we're investing in growth vehicles that keep giving us tailwinds.
That's quite useful, thanks.
Rob Goff from Ventum Financial, you have the floor.
Thanks a lot. One more question about the M&A picture in Canada. Specifically: are you noticing other players turning up, so that you find yourselves in competitive bidding situations, or does it remain largely non-competitive? And from the seller side, are they becoming somewhat more willing to embrace consolidation, given the pressures from automation and digitization, and so on?
Appreciate the questions, Rob. We're certainly encountering competition in certain processes from time to time. One area where we've performed quite well, I'd say, is seeking out distinctive opportunities where no rivals exist and where processes aren't yet organized. Something that has gotten better — I might have brought this up on an earlier conference call — is that we've now truly enabled our own M&A process with technology and AI. Our present M&A process, along with how we identify and originate deals, would be unrecognizable compared with a year ago when it comes to how deeply we understand the market, how deeply we understand margin profiles, growth rates, and who's doing what, and I believe that's really showing a clear advantage for us. I would say that, yes, we do see competitors out there occasionally. I also believe we're likewise attempting to locate distinctive opportunities. On top of that, I think WELL's brand draws people in. I think we've been in a few situations where we're simply viewed as an aspirational company to sell to. That's one of the points. On your second point, I believe you mentioned motivation around automation and digitization.
Does that get people motivated? I'm not convinced it does. For a very long stretch of time, particularly within diagnostics, what we observed was that once multiples came down following the pandemic, many owners simply had no interest in selling. Their minds were fixed on richer multiples. Yes, there is a degree of competition in diagnostics, but I'd characterize it as a small slice compared with what you find in the U.S. Some competition does exist there. As for tech enablement, I don't believe it has really pushed people toward selling more. If anything, my view is that tech enablement relieves pressure on a provider, provided they implement it properly. The trouble for providers is that pulling off that tech enablement on their own is genuinely difficult. That's precisely why, for instance, WELLSTAR bought BlueBird iT — because, and many people fail to appreciate this regarding WELLSTAR, it possesses a quite sizable break-fix maintenance network, with the capability to deploy and manage technology. Naturally, on the WELL side, we offer a complete managed service, and that is among the reasons we do so well with technology — we don't place that burden on the provider.
At WELL, whenever you arrive to carry out your work, you’re surrounded by an entire skilled group of support staff and tech specialists whose job is to help you succeed, and all of it runs on the newest and most advanced technology. What I would say is this: if your question meant whether they wish to join our network so they can take advantage of those technologies, then my answer is yes. I genuinely observe considerable evidence of that, especially when it comes to the absorptions, or the very small number of multiple acquisitions that we undertake.
Excellent. Thanks, and best of luck to you.
Gianluca Tucci from Haywood Securities — go right ahead.
Hey Hamed, congratulations on the quarter. We've just got one question on our side here. Hamed, could you give us an update on the work with the Competition Bureau that's happening at the moment? Thank you.
Yeah. No, thanks, Gianluca. Every information request they asked us for has been turned in, and there have been no further inquiries or genuine conversations with them. So I can't really add much beyond that. Naturally, we've gone through all those same documents on our own, and we believe we're sitting in a very strong position. As you know, we don't believe there's anything anti-competitive about us at all. As you're probably aware, the thing that kicked off this entire process with the Competition Bureau was essentially an oversight by our counsel on the HEALWELL acquisition — that was a notable transaction that didn't receive the proper notice. So we ended up in a different queue at the Competition Bureau. It wasn't really triggered by anything else unusual or anomalous in the marketplace. Look, we have a lot of confidence in what we've done. We are absolutely a company that prizes competition and collaborates very closely with the market. In fact, I'd argue that if you consider something like WELLSTAR's app marketplace, no other company in the country is more open, more standards-based, or more supportive of innovation and connectivity than we are. I think people get that, and I'm optimistic about how that assessment will turn out.
Thanks, Hamed — congratulations once more.
Thanks, Jeff.
Michael Freeman from Raymond James, you have the floor.
Hello, everyone, and thanks for the question. I was hoping we might discuss the UnionMD and OID acquisitions you completed recently. How have they performed during their first month as part of the company? Considering the 25%+ adjusted EBITDA margins they posted historically, what trend do you expect going forward as integration proceeds and as you possibly add capacity? Thank you.
Thanks. That's an excellent question. These two businesses both produce strong margins. Their growth trajectories differ somewhat. What stands out with UnionMD is that it operates as a platform for dermatology and procedural health, and we believe we can fold it successfully into several of our other clinical settings. That genuinely excites us. Beyond having an attractive growth trajectory from its own same-clinic sales growth and from new sites, it also can be integrated and extended. In my view, that one could have a bigger influence on future growth and on its capacity to affect the business. OID performs very well. We have already found them to be highly efficient. We hope to make it a bit better as time goes on; bear in mind that in Ontario, where OID is headquartered, a license is required for everything you do. Remember that alongside these acquisitions, we are also obtaining the licensure underneath, and those licenses carry real cost. If you strip out the underlying expense of those licenses, you will see that the price we paid for these acquisitions was very, very reasonable given their long-term terminal growth and profitability. Broadly speaking, I believe we have experienced above-average organic growth within our diagnostic business.
My sense is that you should keep expecting that sort of growth from us. On your first question, both are performing very well. The first month was excellent, and we now have a good view into where they're headed and feel they will be performing at or better than deal EBITDA.
Alright, thanks Hamed. One last quick item. Could you remind us whether revenue deferrals tied to Circle Medical will carry on into Q3, or whether we’re largely finished with those in Q2?
Yeah, I believe we're basically finished. Eva, would you like to verify that? From what I understand, that's the case.
Sure.
We’re now in the final quarter.
Yes. All of the deferred revenue from 2025 gets fully recognized in Q2 — every bit of it. That process is entirely finished on our end.
The deferral period is over. There you have it.
Got it — that makes it clearer. Okay then. Thanks a lot, and well done.
Thanks to you too. That's much appreciated.
Thanks. That brings today’s Q&A portion to an end. I’ll now hand the call back to Hamed Shahbazi, who will offer some closing remarks.
Thank you so much for being here, everybody. We truly appreciate it. We’re looking forward to talking with you once more in November. In the meantime, we’ll of course keep you updated on the initiatives and catalysts we have coming up. Best wishes.
That brings today’s conference call to a close, everyone. We appreciate your participation, and we ask that you disconnect your line, please.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete WELL Health Technologies Corp. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to WELL Health Technologies Corp. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.